Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Glucose-, lipid-lowering drugs put brakes on CKD progression

13 Oct 2019

Drugs used to modify blood glucose and lipid levels appear to help slow the progression of chronic kidney disease (CKD), suggesting that glycaemic control and lipid regulation may improve renal function in patients with moderate CKD, according to a systematic review and meta-analysis.

Researchers searched multiple online databases for randomized controlled trials evaluating the effect of antihypertensives, lipid-modifying drugs, glycaemic control drugs or sodium bicarbonate vs placebo on the following outcomes: renal function, proteinuria, adverse events, initiation of maintenance dialysis or kidney transplantation, cardiovascular (CV) events, CV mortality and all-cause mortality.

The meta-analysis included 35 trials and more than 51,000 patients aged 40 years with CKD stages 3 and/or 4, with at least 2 years of follow-up. Data were limited, and heterogeneity varied.

Pooled data showed that final renal function (estimated glomerular filtration rate) was higher by 6 percent in patients taking glucose-lowering drugs (ratio of means [ROM], 1.06, 95 percent CI, 1.02–1.10; I2, 0 percent; low GRADE confidence) and by 4 percent in those on lipid-modifying drugs (ROM, 1.04, 1.00–1.08; I2, 88 percent; very low GRADE confidence). Renal function did not significantly change in patients taking antihypertensive drugs.

Furthermore, treatment with lipid-modifying drugs produced a 36-percent reduction in cardiovascular disease and 26-percent decrease in all-cause mortality.

Researchers pointed out that the findings are tentative, given the limited data and high heterogeneity for many of the analyses. Therefore, additional studies evaluating the effects of drugs on the progression in CKD are needed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.